Skin and Soft Tissue Infection Treatment Market: Overview
Skin and soft tissue infections (SSTIs) are one of the most common infections present in inpatient as well as outpatients. Skin and soft tissue infections (SSTIs) comprise of various minor and major infections of skin, fascia, subcutaneous tissue and muscle. These infections include such as impetigo, folliculitis, furuncles, carbuncles, erysipelas, cellulitis, necrotizing fasciitis and pyomyositis. These infections may be associated with an underlying cause such as diabetes or systemic immunosuppression.
Skin and soft tissue infections (SSTIs) may be caused by any of the pathogenic microorganisms which include Staphylococcus aureus, Streptococcus pyogene, gram-negative bacilli, Pseudomonas aeruginosa, beta-hemolytic streptococci, Enterococcus, streptococci, staphylococci, Peptostreptococcus, Bacteroides, Clostridium and S. pyogenes. Methicillin-resistant Staphylococcus aureus (MRSA) and streptococci are the most common organisms causing skin and soft tissue infections (SSTIs).
Obtain Report Details: http://www.transparencymarketresearch.com/skin-soft-tissue-infection-treatment-market.html
Skin and Soft Tissue Infection Treatment Market: Segmentation
The market for skin and soft tissue infections treatment is analyzed based on the medications used for its treatment which includes antibiotics and anti-fungal agents. Traditionally, use of beta-lactam antibiotics has proved to be beneficial against various skin and soft tissue infections. However, with rising use of these traditional medications has led to resistance of these bacteria against the beta-lactam antibiotics.
Moreover, new strains of infectious bacteria urge the need for development of new therapies. Consequently physicians have started using the third-generation antibiotics such as cephalosporins, fluoroquinolones or extended-spectrum agents such as amoxicillin and clavulanic acid. The selection of an appropriate drug depends on the causative microorganism. Besides medications, imaging tools and surgical methods are also practiced for the treatment of skin and soft tissue infections (SSTIs).
Skin and Soft Tissue Infection Treatment Market: Key Trends
The rising incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections has resulted in the need for new therapies to combat the serious skin and soft tissue infections. In addition, new product developments will drive the skin and soft tissue infections treatment market. Recently, in February 2014, Cubist Pharmaceuticals, Inc. announced that its Marketing Authorization Application (MAA) for investigational candidate tedizolid phosphate has been accepted by the European Medicines Agency (EMA) for review. With a decision expected from the European Commission (EC) during the first half of 2015, the company seeks to market its new product for the treatment of skin and soft tissue infections.
Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13349
Prior to EMA, the U.S. FDA accepted company’s New Drug Application (NDA) for review and the company had also planned for submitting a New Drug Submission (NDS) in Canada in 2014 for tedizolid intended for the treatment of skin and soft tissue infections. Moreover, in December 2013, Durata Therapeutics, Inc. announced the acceptance of its Marketing Authorization Application (MAA) for dalbavancin, intended for the treatment of skin and soft tissue infections, by the European Medicines Agency (EMA) for review.
The Infectious Diseases Society of America has recently released guidelines for the diagnosis and management of skin and soft tissue infections (SSTIs). This practice guideline is to guide the physicians in proper diagnosis and efficient treatment of the skin and soft tissue infections and avoid serious consequences. Based on geography, the skin and soft tissue infections treatment market is analyzed into North America, Europe, Asia-Pacific and Rest of the World.
Skin and Soft Tissue Infection Treatment Market: Key Players
Some of the companies engaged in the development of skin and soft tissue infection (SSTI) treatment medications include Cubist Pharmaceuticals, Inc., Wockhardt Limited, Atox Bio Inc., Durata Therapeutics, Inc., Basilea Pharmaceutica AG, and Melinta Therapeutics Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453